U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07025785) titled 'Molecular Residual Disease Assessment in a Diverse Population of Patients With Early-stage Breast Cancer' on June 09.
Brief Summary: The purpose of this study is to determine how circulating tumor DNA (ctDNA), a sign of minimal residual disease (MRD), is detectable after surgery in patients with early HR+/HER2- breast cancer that has spread to 1-3 lymph nodes. Researchers aim to understand if ctDNA detection can identify patients at higher risk of recurrence and guide better treatment decisions. A key aspect is the inclusion of a dedicated cohort of African American/Black women, a group underrepresented in molecular residual disease...